A Phase 2 Trial - Combination Therapy of Ibrexafungerp (SCY-078) with Voriconazole in Patients with Invasive Pulmonary AspergillosisLearn more here
Ibrexafungerp for Recurrent Vulvovaginal Candidiasis (RVVC)
SCY-0789-304 is a Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) Compared to Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC). Enrollment is complete.
ClinicalTrials.gov Identifier: NCT04029116Learn more here
Phase 3b, open-label, multicenter study to evaluate the efficacy, safety and tolerability of oral ibrexafungerp as a treatment for complicated vulvovaginal candidiasis (VVC) in patients who have failed treatment with fluconazole, based on mycological and clinical outcomes.Learn more here